Form 8-K - Current report:
SEC Accession No. 0001628280-23-038594
Filing Date
2023-11-13
Accepted
2023-11-13 16:03:06
Documents
14
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ryzb-20231113.htm   iXBRL 8-K 28417
2 EX-99.1 ryzb-20231113xexx991.htm EX-99.1 53731
6 image.jpg GRAPHIC 10600
  Complete submission text file 0001628280-23-038594.txt   238860

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ryzb-20231113.xsd EX-101.SCH 1892
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ryzb-20231113_lab.xml EX-101.LAB 26155
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ryzb-20231113_pre.xml EX-101.PRE 13575
8 EXTRACTED XBRL INSTANCE DOCUMENT ryzb-20231113_htm.xml XML 2911
Mailing Address 5505 MOREHOUSE DRIVE, SUITE 300 SAN DIEGO CA 92121
Business Address 5505 MOREHOUSE DRIVE, SUITE 300 SAN DIEGO CA 92121 (619) 937-2754
RayzeBio, Inc. (Filer) CIK: 0001825367 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41799 | Film No.: 231398498
SIC: 2834 Pharmaceutical Preparations